4//SEC Filing
BAILEY MICHAEL P 4
Accession 0001628280-22-032490
CIK 0001325879other
Filed
Dec 21, 7:00 PM ET
Accepted
Dec 22, 4:46 PM ET
Size
14.3 KB
Accession
0001628280-22-032490
Insider Transaction Report
Form 4
BAILEY MICHAEL P
Chief Commercial Officer
Transactions
- Exercise/Conversion
Common Stock
2022-12-20$5.60/sh+85,722$480,043→ 175,642 total - Exercise/Conversion
Common Stock
2022-12-20$3.67/sh+164,525$603,807→ 340,167 total - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−85,722→ 35,302 totalExercise: $5.60Exp: 2030-02-05→ Common Stock (85,722 underlying) - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−164,525→ 625,192 totalExercise: $3.67Exp: 2032-02-15→ Common Stock (164,525 underlying) - Exercise/Conversion
Common Stock
2022-12-20$6.20/sh+26,499$164,294→ 82,920 total - Exercise/Conversion
Stock Option (right to buy)
2022-12-20−26,499→ 93,500 totalExercise: $6.20Exp: 2029-02-06→ Common Stock (26,499 underlying)
Footnotes (4)
- [F1]Includes 7,110 shares purchased by the Reporting Person under the Company's 2010 Employee Stock Purchase Plan, as amended.
- [F2]The shares underlying this option vest in equal monthly installments from February 6, 2019 through February 6, 2023, subject to the Reporting Person's continued service to the Company.
- [F3]The shares underlying this option vest in equal monthly installments from February 5, 2020 through February 5, 2024, subject to the Reporting Person's continued service to the Company.
- [F4]The shares underlying this option vest in equal monthly installments from February 15, 2022 through February 15, 2026, subject to the Reporting Person's continued service to the Company.
Documents
Issuer
AVEO PHARMACEUTICALS, INC.
CIK 0001325879
Entity typeother
Related Parties
1- filerCIK 0001255856
Filing Metadata
- Form type
- 4
- Filed
- Dec 21, 7:00 PM ET
- Accepted
- Dec 22, 4:46 PM ET
- Size
- 14.3 KB